Krystal Biotech (FRA:4KB) PE Ratio: 47.30 (As of Jun. 26, 2026) — Near Median


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €303.60
GF Value €263.13
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech PE Ratio?

Krystal Biotech FRA:4KB +2.29% 58 PE Ratio is 47.30 as of Jun. 26, 2026, which is 2% below its 10-year median of 48.26. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €263.13 (Modestly Overvalued). The stock has 6 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-26), Krystal Biotech's share price is €303.60. Krystal Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €6.42. Therefore, Krystal Biotech's PE Ratio for today is 47.30.

Warning Sign:

Krystal Biotech Inc stock PE Ratio (=48.12) is close to 1-year high of 48.12.

During the past 10 years, Krystal Biotech's highest PE Ratio was 1977.00. The lowest was 27.21. And the median was 48.26.

Krystal Biotech's EPS (Diluted) for the three months ended in Mar. 2026 was €1.58. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €6.42.

As of today (2026-06-26), Krystal Biotech's share price is €303.60. Krystal Biotech's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €6.42. Therefore, Krystal Biotech's PE Ratio without NRI ratio for today is 47.30.

During the past 10 years, Krystal Biotech's highest PE Ratio without NRI was 206.43. The lowest was 25.26. And the median was 36.92.

Krystal Biotech's EPS without NRI for the three months ended in Mar. 2026 was €1.58. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €6.42.

During the past 12 months, Krystal Biotech's average EPS without NRI Growth Rate was 51.10% per year.

During the past 10 years, Krystal Biotech's highest 3-Year average EPS without NRI Growth Rate was -4.90% per year. The lowest was -64.60% per year. And the median was -47.80% per year.

Krystal Biotech's EPS (Basic) for the three months ended in Mar. 2026 was €1.65. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €6.65.

Back to Basics: PE Ratio


Krystal Biotech  (FRA:4KB) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Krystal Biotech PE Ratio Related Terms


Krystal Biotech PE Ratio Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech PE Ratio Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss 318.10 52.22 36.04

Krystal Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.34 27.94 26.47 36.04 34.53

FRA:4KB vs NUVL, PRAX, TECH: PE Ratio Comparison

For the Biotechnology subindustry, Krystal Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's PE Ratio falls into.


FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Krystal Biotech's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=303.60/6.419
=47.3

Krystal Biotech's Share Price of today is €303.60.
Krystal Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.42.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 47.30 mean?
Krystal Biotech (FRA:4KB) has a PE Ratio of 47.30 as of Jun. 26, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Krystal Biotech and its competitors. This is near median its historical median of 48.26. Over the past decade, Krystal Biotech's PE Ratio has ranged from 27.21 to 1,977.00.
Is Krystal Biotech's PE Ratio too high?
Krystal Biotech's current PE Ratio of 47.30 is near median its 10-year median of 48.26. Over the past 10 years, this metric has ranged from a low of 27.21 to a high of 1,977.00. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's PE Ratio compare to NUVL and PRAX?
Krystal Biotech's PE Ratio of 47.30 can be compared against companies in the Biotechnology industry. Historically, Krystal Biotech's own PE Ratio has ranged from 27.21 to 1,977.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Biotechnology company?
A good PE Ratio depends on the Biotechnology industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current PE Ratio is 47.30, which is near median its own 10-year median of 48.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €263.13, compared to a current price of €303.60 — trading 15.4% above its estimated fair value. The current PE Ratio is 47.30, which is near median its 10-year median of 48.26. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current PE Ratio is 47.30 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • PE Ratio: 47.30 (near median its 10-year median of 48.26)
  • GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€303.60
Price
€263.13
GF Value